Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Net Cash Flow (2016 - 2026)

Ovid Therapeutics filings provide 11 years of Net Cash Flow readings, the most recent being $81.0 million for Q1 2026.

  • Quarterly Net Cash Flow rose 1668.89% to $81.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $73.3 million through Mar 2026, up 860.26% year-over-year, with the annual reading at -$12.9 million for FY2025, 1649.59% down from the prior year.
  • Net Cash Flow hit $81.0 million in Q1 2026 for Ovid Therapeutics, up from -$7.3 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $81.0 million in Q1 2026 and bottomed at -$93.9 million in Q2 2022.
  • Average Net Cash Flow over 5 years is -$5.5 million, with a median of -$7.3 million recorded in 2025.
  • The largest annual shift saw Net Cash Flow plummeted 349.4% in 2022 before it skyrocketed 1668.89% in 2026.
  • Ovid Therapeutics' Net Cash Flow stood at -$13.4 million in 2022, then tumbled by 127.01% to -$30.4 million in 2023, then soared by 137.13% to $11.3 million in 2024, then plummeted by 164.31% to -$7.3 million in 2025, then skyrocketed by 1216.62% to $81.0 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Net Cash Flow are $81.0 million (Q1 2026), -$7.3 million (Q4 2025), and -$7.8 million (Q3 2025).